US EditionCARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
- CARsgen Therapeutics Holdings Limited has successfully defended its European patent EP3445407 for GPC3 CAR-T cell therapy at the European Patent Office following a favorable decision.
- On July 3, 2025, the sole appellant withdrew its appeal against the EPO's decision, making it final and binding.
- The EPO upheld key claims regarding GPC3 CAR-T cell therapy after reviewing the case.
- This outcome strengthens CARsgen's intellectual property position in GPC3-targeted CAR-T therapies for solid tumors.
Insights by Ground AI
Does this summary seem wrong?
64 Articles
64 Articles
CARsgen Wins GPC3 CAR-T Patent Battle at EPO
SHANGHAI, July 14, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the European Patent Office (EPO) concerning its European patent EP3445407, which covers its GPC3-targeted CAR-T cell therapy. On July 3, 2025, a U.S.-based biotechnology — the sole appellant among the original two oppone…
Coverage Details
Total News Sources64
Leaning Left10Leaning Right5Center22Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 27%
C 59%
14%
Factuality
To view factuality data please Upgrade to Premium
